

David Jayne

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11960928/david-jayne-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

13,890
citations

52
h-index

117
g-index

165
ext. papers

17,714
ext. citations

6
avg, IF

6.05
L-index

#	Paper	IF	Citations
155	A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. <i>New England Journal of Medicine</i> , 2003 , 349, 36-44	59.2	1024
154	Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1103-12	12.7	718
153	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
152	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
151	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 488-94	2.4	501
150	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
149	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). <i>American Journal of Clinical Pathology</i> , 1999 , 111, 507-13	1.9	466
148	Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. <i>Annals of Internal Medicine</i> , 2005 , 143, 632-8	8	449
147	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1921-1932	59.2	416
146	Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. <i>New England Journal of Medicine</i> , 2011 , 365, 1886-95	59.2	413
145	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 605-17	2.4	394
144	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
143	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
142	Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 717-21	12.7	292
141	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 955-60	2.4	278
140	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015 , 26, 545-53	3.9	254
139	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1036-43	2.4	253

138	Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology</i> , 2010 , 49, 128-40	3.9	224
137	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 542-8		223
136	Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2368-79		201
135	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007 , 57, 686-93		193
134	Position paper: Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 683-692	8.1	183
133	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012 , 11, 357-64	13.6	176
132	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
131	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173
130	Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. <i>Trials</i> , 2013 , 14, 73	2.8	162
129	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018 , 57, e1-e45	3.9	150
128	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 344-53	8.8	150
127	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. <i>Arthritis Care and Research</i> , 2010 , 62, 1166-73	4.7	148
126	Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 177-84	2.4	143
125	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , 2004 , 13, 168-76	2.6	143
124	Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011 , 57, 566-74	7.4	131
123	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011 , 63, 588-96	4.7	116
122	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1744-50	2.4	114
121	Update on the European Vasculitis Study Group trials. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 48-55	5.3	111

120	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 399-405	2.4	102
119	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1662-1668	2.4	100
118	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017 , 16, 1-9	13.6	98
117	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013 , 15 Suppl 1, S2	5.7	94
116	Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 968-75	6.9	91
115	Diagnosis and management of ANCA associated vasculitis. <i>BMJ, The</i> , 2012 , 344, e26	5.9	77
114	ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1764-9	4.3	76
113	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018 , 70, 571-581	4.7	74
112	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015 , 54, 471-81	3.9	73
111	Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 3307-14	4.3	62
110	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>European Respiratory Journal</i> , 2016 , 48, 1429-1441	13.6	61
109	Development of comprehensive disease assessment in systemic vasculitis. <i>Postgraduate Medical Journal</i> , 2007 , 66, 283-92	2	60
108	Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 814-21	4.3	58
107	Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. <i>Journal of Rheumatology</i> , 2014 , 41, 325-33	4.1	58
106	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , 2011 , 50, 697-702	3.9	58
105	Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). <i>Arthritis Care and Research</i> , 2016 , 68, 374-87	4.7	56
104	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009 , 9, 82-9	13.6	54
103	The diagnosis of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 445-53	5.3	50

102	The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012 , 12, 204-9	13.6	49
101	Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 12-7	5.3	48
100	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018 , 57, 470-479	3.9	47
99	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2071-4	2.4	47
98	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 63-73	4.3	47
97	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 952-963	9.5	46
96	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2170-2177	11.5	41
95	Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018 , 70, 109-114	9.5	40
94	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 580-591	8.1	39
93	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 80-5	2.4	39
92	Review article: Progress of treatment in ANCA-associated vasculitis. <i>Nephrology</i> , 2009 , 14, 42-8	2.2	39
91	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019 , 5, e000905	5.9	37
90	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 613-20	7.4	37
89	Management of alveolar hemorrhage in lung vasculitides. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011 , 32, 335-45	3.9	37
88	End-stage renal disease in ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 248-253	4.3	37
87	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102618	13.6	36
86	Switching of anti-TNF- α agents in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S62-8	2.2	36
85	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35

84	Non-transplant uses of mycophenolate mofetil. <i>Current Opinion in Nephrology and Hypertension</i> , 1999 , 8, 563-7	3.5	34
83	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017 , 7, 5088	4.9	31
82	Current attitudes to the therapy of vasculitis. <i>Kidney and Blood Pressure Research</i> , 2003 , 26, 231-9	3.1	30
81	Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's). <i>European Archives of Oto-Rhino-Laryngology</i> , 2013 , 270, 345-54	3.5	29
80	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , 2009 , 48, 823-7	3.9	29
79	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
78	Challenges in the management of microscopic polyangiitis: past, present and future. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 3-9	5.3	28
77	Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients. <i>Arthritis and Rheumatology</i> , 2016 , 68, 713-23	9.5	28
76	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017 , 19, 129	5.7	26
75	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 741-758	12.7	26
74	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1357-71	4.1	26
73	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018 , 3, 1039-1049	4.1	25
72	Diagnosis and treatment of kidney disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 785-98	5.3	24
71	Mycophenolate mofetil for remission induction in severe lupus nephritis. <i>Nephron Clinical Practice</i> , 2005 , 100, c92-100		24
70	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018 , 57, 14-18	3.9	23
69	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1243-1249	2.4	22
68	Outcome assessment in Takayasu arteritis. <i>Rheumatology</i> , 2016 , 55, 1159-71	3.9	21
67	The pulmonary vasculitides. <i>Clinics in Chest Medicine</i> , 2010 , 31, 519-36	5.3	19

66	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2019 , 58, 260-268	3.9	19
65	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017 , 2, 1018-1031	4.1	17
64	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 951-962	5.1	17
63	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Rheumatology</i> , 2017 , 56, 704-708	3.9	16
62	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
61	Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 1-6	5.3	15
60	Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 1, i1-7	4.3	14
59	Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. <i>Journal of Nephrology</i> , 2015 , 28, 17-27	4.8	14
58	Complement inhibition in ANCA vasculitis. <i>Nephrologie Et Therapeutique</i> , 2019 , 15, 409-412	0.6	14
57	How to induce remission in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 293-305	5.3	14
56	International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 ,	10.2	13
55	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. <i>RMD Open</i> , 2020 , 6,	5.9	13
54	ANCA-Associated Vasculitis: An Update. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	13
53	Sustained remission in lupus nephritis: still a hard road ahead. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 2011-2018	4.3	11
52	ANCA associated vasculitis: The journey to complement-targeted therapies. <i>Molecular Immunology</i> , 2019 , 112, 394-398	4.3	11
51	Long-term damage to the ENT system in Wegener's granulomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011 , 268, 733-9	3.5	11
50	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 301-308	4.3	10
49	Pulmonary-Renal Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1998 , 19, 69-77	3.9	10

48	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021 , 60, 359-365	3.9	10
47	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
46	Newer therapies for vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 379-89	5.3	9
45	Treatment of ANCA-associated systemic small-vessel vasculitis. <i>Apmis</i> , 2009 , 117, 3-9	3.4	9
44	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019 , 14, 1193-1197	3.7	8
43	A disease activity score for ENT involvement in granulomatosis with polyangiitis (Wegener's). <i>Laryngoscope</i> , 2013 , 123, 622-8	3.6	7
42	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
41	New biologics for glomerular disease on the horizon. <i>Nephron Clinical Practice</i> , 2014 , 128, 283-91		6
40	Rituximab treatment for vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1359-62	6.9	6
39	Clinical management and treatment of vasculitis. <i>Seminars in Immunopathology</i> , 2001 , 23, 267-86		6
38	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1314-1325	5.3	6
37	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021 , 60, 4355-4360	3.9	5
36	Clinical Trials in Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2016 , 2, 161-177	1.3	5
35	New-generation therapy for ANCA-associated vasculitis. <i>Clinical and Experimental Nephrology</i> , 2013 , 17, 694-696	2.5	5
34	L27. Antibodies versus phenotypes: a clinician's view. <i>Presse Medicale</i> , 2013 , 42, 579-82	2.2	5
33	Current modalities in the diagnosis of pulmonary vasculitis. <i>Expert Opinion on Medical Diagnostics</i> , 2012 , 6, 499-516		5
32	Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021 , 60, 2745-2754	3.9	5
31	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1673-1682	9.5	5

30	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , 2021 , 74, 295	9.5	5
29	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. <i>Lupus Science and Medicine</i> , 2019 , 6, e000308	4.6	4
28	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , 2019 , 10, 37-42	2.9	4
27	Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	4
26	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019 , 86, 363-368	2.9	4
25	Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 784-791	9.5	4
24	Lupus Nephritis 2010 , 308-321		3
23	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	3
22	Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. <i>Lupus Science and Medicine</i> , 2019 , 6, e000337	4.6	3
21	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2015 , 43, 538-544	0.6	2
20	S2. Rituximab for ANCA-associated vasculitis: the UK experience. <i>Presse Medicale</i> , 2013 , 42, 532-4	2.2	2
19	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2011 , 39, 486-491	0.6	2
18	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	2
17	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1175-1182	2.4	2
16	Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e20	2.4	2
15	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1134-1138	5.3	2
14	Reply: To PMID 22614882. <i>Arthritis and Rheumatism</i> , 2013 , 65, 844		1
13	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 569-70	2.4	1

12	Chapter 8 ANCA-Associated Vasculitis: Clinical Features and Treatment. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007 , 139-157	0.3	1
11	Predictors of outcome in renal vasculitis. <i>Nephrology</i> , 2004 , 9, 254-5	2.2	1
10	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—the Berlin Roadmap. <i>Kidney International Reports</i> , 2016 , 1, 327-339	4.1	1
9	Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. <i>Rheumatology</i> , 2021 , 60, 4538-4547	3.9	1
8	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 82-89	0.2	0
7	Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).. <i>Arthritis Research and Therapy</i> , 2022 , 24, 81	5.7	0
6	Le Relapsing Polychondritis Damage Index (RPDAM) : développement d'un score clinique au cours de la polychondrite atrophiante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020 , 87, 122-127	0.1	
5	Renal Vasculitis in the Elderly 2008 , 373-384		
4	Prognosis and Outcomes of ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , 2020 , 293-311		
3	Immune Vasculitis1-8		
2	Response to: 'Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones by Vandergheynst. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e101	2.4	
1	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152021	5.3	